ACTRN12623000035628尚未招募2 期
A Phase 2, Double Blind Placebo-Controlled Study of BIT225, an Orally Administered SARS-CoV-2 Viroporin Inhibitor, to Evaluate Antiviral Activity, Safety, and Immune Biomarkers in Non-Hospitalised Vaccinated and Unvaccinated Adults with COVID-19.
Biotron Limited0 个研究点目标入组 60 人开始时间: 2023年1月13日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 59 Years（—）
- 性别
- All
入选标准
- •1.Non-hospitalised, males or females aged 18-59 years with symptoms of mild to moderate SARS-CoV-2, including any cough, sore throat, fever, chills, nasal discharge, shortness of breath, fatigue, myalgias, malaise, headache, nausea, vomiting, diarrhea, alteration of taste or smell, that in the opinion of the Investigator are consistent with a presumptive diagnosis of SARS-CoV-2.
- •2.Rapid Antigen Test or PCR evidence confirming infection with SARS-CoV-2; documentation of a positive test within the past 24 hours.
- •3.Symptoms of =/< 3 days consistent with acute SARS-CoV-2 infection.
- •4.Room air oxygen saturation >/= 93%
- •5.Participants may have mild or well controlled comorbid conditions.
- •6.SARS-CoV-2 vaccinated, or unvaccinated individuals will be eligible for screening and enrolment.
- •7.Females of reproductive potential (defined as women who have not been post-menopausal for at least 12 consecutive months, i.e., who have had menses within the preceding 12 months, or women who have not undergone surgical sterilisation via hysterectomy, bilateral salpingectomy and/or bilateral oophorectomy and/or tubal ligation), must:
- •Have a negative serum or urine pregnancy test with a sensitivity of at least 50 mlU/mL at Screening
- •8.All participants must agree not to participate in a conception process (e.g., active attempt to become pregnant, or to impregnate, sperm donation, in vitro fertilization). If participating in sexual activity that could lead to pregnancy, the participant and partner must agree to use reliable methods of contraception while receiving study treatment.
- •9.Participants who are not of reproductive potential (women who have been post-menopausal for at least 12 consecutive months or have undergone hysterectomy, bilateral salpingotomy, and/or bilateral oophorectomy or men who have documented azoospermia) are eligible without requiring the use of contraceptives.
- •10.Provide written informed consent to participate in the study and be willing to comply with the study procedures
排除标准
- •1.Individuals who would be excluded following the current Thai Ministry of Public Health (MOPH) COVID-19 National Guidelines.
- •2.In the opinion of the investigator, any participant who is likely to require hospitalisation, for any reason, within the next 48 hours.
- •3.Participants who have received non-vaccination treatment for SARS-CoV-2 within 30 days prior to study entry, e.g., remdesivir, Paxlovid, molnuparivir, SARS-CoV-2 monoclonal Abs, convalescent serum, or other anti- SARS-CoV-2 agents with national regulatory approval, zinc, or Andrographis paniculata.
- •4.Known current, or past, history of clinically significant arrhythmia.
- •5.Screening ECG QTcF value >/= 450 ms.
- •6.Pregnancy or breastfeeding.
- •7.Serious illness, that in the opinion of the site Investigator, is not considered medically stable.
- •8.Hospitalisation, for any reason, within the past 7 days.
- •9.The consumption / administration of excluded concomitant medication at the time of the Screening visit or during the treatment course of the study.
- •10.Active drug or alcohol use or dependence that, in the opinion of the site Investigator, would interfere with adherence to study requirements or compromise participant safety.
- •11.Known allergy/sensitivity or any hypersensitivity to components of study drug or its formulation
- •12.Presence of a condition, that in the opinion of the Investigator, would place the participant at increased risk from study participation, or compromise data integrity.
研究者
相似试验
进行中（未招募）
不适用
A Phase 2 study to test how effective MEDI8968 is in treating subjects with chronic bronchitis, emphysema, or both, in which airflow to the lungs is restricted.Chronic Obstructive Pulmonary DiseaseMedDRA version: 14.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2011-002563-23-LTMedImmune Limited300
进行中（未招募）
不适用
A Phase 2 study to test how effective MEDI8968 is in treating subjects with chronic bronchitis, emphysema, or both, in which airflow to the lungs is restricted.Chronic Obstructive Pulmonary DiseaseMedDRA version: 14.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2011-002563-23-PLMedImmune Limited300
进行中（未招募）
不适用
A Phase 2 study to test how effective MEDI8968 is in treating subjects with chronic bronchitis, emphysema, or both, in which airflow to the lungs is restricted.Chronic Obstructive Pulmonary DiseaseEUCTR2011-002563-23-HUMedImmune Limited300
进行中（未招募）
1 期
A Phase 2 study to test how effective MEDI8968 is in treating subjects with chronic bronchitis, emphysema, or both, in which airflow to the lungs is restricted.Chronic Obstructive Pulmonary DiseaseEUCTR2011-002563-23-GBMedImmune Limited324
进行中（未招募）
不适用
A Phase 2 study to test how effective MEDI8968 is in treating subjects with chronic bronchitis, emphysema, or both, in which airflow to the lungs is restricted.Chronic Obstructive Pulmonary DiseaseMedDRA version: 14.0Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2011-002563-23-LVMedImmune Limited300